Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab Post-SCT for High-Risk MDS and AML
NCT04361058Phase 1Withdrawn
- Sponsor
- SCRI Development Innovations
- Start
- Apr 2020
- Primary completion
- Apr 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of nivolumab in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (2 arms), sponsored by SCRI Development Innovations. Primary endpoint: Incidence of dose limiting toxicities at 28 days. Planned start Apr 2020; status: withdrawn.
02
Drugs
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04361058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04361058.